BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 12634977)

  • 1. Do we read carefully?
    Medvedec M
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):475-6. PubMed ID: 12634977
    [No Abstract]   [Full Text] [Related]  

  • 2. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
    Lees W; Mansberg R; Roberts J; Towson J; Chua E; Turtle J
    Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1421-7. PubMed ID: 12397458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-body scanning with radionuclides of iodine, and the controversy of "thyroid stunning".
    Kalinyak JE; McDougall IR
    Nucl Med Commun; 2004 Sep; 25(9):883-9. PubMed ID: 15319592
    [No Abstract]   [Full Text] [Related]  

  • 4. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
    Cholewinski SP; Yoo KS; Klieger PS; O'Mara RE
    J Nucl Med; 2000 Jul; 41(7):1198-202. PubMed ID: 10914909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
    Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Technetium-99m tetrofosmin uptake in insular thyroid carcinoma. A comparison with iodine-131.
    Degirmenci B; Aydin A; Comlekci A; Ozdogan O; Bekis R
    Clin Nucl Med; 2003 May; 28(5):385-8. PubMed ID: 12702934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid remnant ablation following administration of a diagnostic dose of iodine-131 under thyrogen stimulation.
    Wu D; Fink-Bennett D; Campbell J
    Thyroid; 2014 May; 24(5):924-5. PubMed ID: 24483713
    [No Abstract]   [Full Text] [Related]  

  • 8. Stunning with 131I diagnostic whole-body imaging of patients with thyroid cancer.
    Gerard SK; Dam HQ
    Radiology; 2005 Mar; 234(3):972-3; author reply 973-4. PubMed ID: 15734947
    [No Abstract]   [Full Text] [Related]  

  • 9. The continuous debate in literature about the usage of iodine-131 dosing for the ablation of thyroid remnants and metastases.
    De Klerk JM; Oyen WJ
    Minerva Endocrinol; 2009 Mar; 34(1):57-69. PubMed ID: 19209128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term effectiveness of low-dose radioiodune ablative treatment of thyroid remnants after thyroidectomy for differentiated thyroid cancer.
    Vermiglio F; Violi MA; Finocchiaro MD; Baldari S; Castagna MG; Moleti M; Mattina F; Pio Lo Presti V; Bonanno N; Trimarchi F
    Thyroid; 1999 Apr; 9(4):387-91. PubMed ID: 10319946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Level of Agreement Between Pretherapeutic 124I PET and Intratherapeutic 131I Imaging in Detecting Iodine-Positive Thyroid Cancer Metastases.
    Ruhlmann M; Jentzen W; Ruhlmann V; Pettinato C; Rossi G; Binse I; Bockisch A; Rosenbaum-Krumme S
    J Nucl Med; 2016 Sep; 57(9):1339-42. PubMed ID: 27151981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. False-positive "necklace sign" on whole-body thyroid cancer survey--a case report.
    Beaulieu S; Djang D; Minoshima S
    J Nucl Med Technol; 2005 Mar; 33(1):42-3. PubMed ID: 15731020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of iodinated contrast agent administered during preoperative computed tomography scan on body iodine pool in patients with differentiated thyroid cancer preparing for radioactive iodine treatment.
    Sohn SY; Choi JH; Kim NK; Joung JY; Cho YY; Park SM; Kim TH; Jin SM; Bae JC; Lee SY; Chung JH; Kim SW
    Thyroid; 2014 May; 24(5):872-7. PubMed ID: 24295076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Iodine uptake in the chest in the follow-up of well-differentiated thyroid cancer].
    García Alonso MP; Balsa Bretón MA; Paniagua Correa C; Castillejos Rodríguez L; Penín González FJ; Elviro Peña R; Ortega Valle A; Mariana Monguía A; Vásquez Tineo SI; Mendoza Paulini A; Pey Illera C
    Rev Esp Med Nucl; 2011; 30(1):24-8. PubMed ID: 20863596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
    Dam HQ; Kim SM; Lin HC; Intenzo CM
    Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postsurgical thyroid remnant estimation by (⁹⁹m) Tc-pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.
    Giovanella L; Suriano S; Ricci R; Ceriani L; Anton Verburg F
    Head Neck; 2011 Apr; 33(4):552-6. PubMed ID: 20824809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. I-123 uptake by intrathoracic stomach.
    Sathekge MM; Mokgoro NP; Mpikashe P; Ramafi OE
    Clin Nucl Med; 2005 Jan; 30(1):42. PubMed ID: 15604972
    [No Abstract]   [Full Text] [Related]  

  • 18. Visual vignette.
    Satya R; Muthukrishnan A; Rosenthal RS; Ojha BC
    Endocr Pract; 2004; 10(4):384. PubMed ID: 15760785
    [No Abstract]   [Full Text] [Related]  

  • 19. Should high hTg levels in the absence of iodine uptake be treated?
    Britton KE; Foley RR; Chew SL
    Eur J Nucl Med Mol Imaging; 2003 May; 30(5):794-5. PubMed ID: 12616324
    [No Abstract]   [Full Text] [Related]  

  • 20. Stunning after tracer dosimetry.
    Diehl M; Grünwald F
    J Nucl Med; 2001 Jul; 42(7):1129. PubMed ID: 11438639
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.